Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ProPhase Labs, Inc. | v244509_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
______________________
Date of Report (Date of earliest event reported): January 2, 2012
PROPHASE LABS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
(State or other
jurisdiction of incorporation)
|
0-21617
(Commission
File Number)
|
23-2577138
(I.R.S. Employer
Identification No.)
|
|
621 N. Shady Retreat Road
Doylestown, PA
|
18901
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: (215) 345-0919
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On January 2, 2012, The Tan Sheet, an OTC trade source publication, published an article under the headline “CEO Karkus Talks Cold-EEZE Turnaround At “Lean, Mean” ProPhase Labs.” A copy of that article is attached as Exhibit 99.1.
The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
No.
|
Description
|
|
|
99.1
|
The Tan Sheet Article, published January 2, 2012
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ProPhase Labs, Inc. | |||
|
|
By:
|
/s/ Robert V. Cuddihy, Jr. | |
| Robert V. Cuddihy, Jr. | |||
| Chief Financial Officer | |||
| Chief Operating Officer | |||
Date: January 3, 2012
EXHIBIT INDEX
|
No.
|
Description
|
|
|
99.1
|
The Tan Sheet Article, published January 2, 2012
|